$TWOU Harvard Business School, Business Analytics Program Partnership

BOSTON and LANHAM, Md., Aug. 7, 2017  — 2U, Inc. (NASDAQ: TWOU) today announced a new partnership with Harvard Business School (HBS), the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and the Department of Statistics in the Faculty of Arts and Sciences, to deliver the Harvard Business Analytics Program.

The new executive certificate program is designed for business leaders, including MBA graduates, seeking to modernize their analytics skills and learn new ways to analyze, interpret and take advantage of increasingly complex data across all industries. Digital technologies are becoming pervasive in all types of organizations, leading to an explosion in the velocity, variety, and volume of data being generated and consumed by the enterprise and its stakeholders. Executives need to be fluent in how to effectively leverage data and analytics to drive business impact in both the organization’s business and operating model.

Program participants get exposed to cutting edge research on how data-driven business analytics impacts strategy, operations, marketing, people management and leadership.  At the same time they develop core skills in the fundamentals of analytics, software design and architecture, and data science to be able to take advantage of the opportunities that exist in a data-centric business environment.

“By bringing together world-class faculty from Harvard Business School, the Harvard John A. Paulson School of Engineering and Applied Sciences and the Faculty of Arts and Sciences, the Harvard Business Analytics Certificate Program will push the boundaries of innovation in terms of both scholarship and program delivery,” said Srikant Datar, Senior Associate Dean for University Affairs at HBS. “Business analytics is an exciting emerging field and Harvard is uniquely positioned to collaborate across disciplines and geographies in pursuit of new ideas in this space.”

“Our partnership with Harvard, one of the world’s most revered educational institutions, to jointly deliver a truly innovative business certificate is a powerful example of 2U’s leadership in working with universities to deliver programs that provide working professionals the skills they need to succeed in today’s technology and data driven economy,” said Christopher “Chip” Paucek, 2U CEO and co-founder.

The program will provide a flexible, top-flight online learning experience, eliminating the need for students to relocate in order to pursue business studies. The first cohort of students is expected start classes in March 2018.

The Harvard Business Analytics Certificate Program will match the high quality and rigorous standards of other Harvard Business School programs. It will feature live, face-to-face online classes in an intimate seminar-style setting as well as engaging, interactive course content created by HBS, SEAS and Statistics faculty and delivered through the 2U platform. Students will participate in two on-campus learning experiences at the Harvard Business School campus in Boston.

For more information, visit analytics.hbs.edu.

About Harvard Business School
Founded in 1908 as part of Harvard University, Harvard Business School is located on a 40-acre campus in Boston. Its faculty of more than 200 offers full-time programs leading to the MBA and doctoral degrees, as well as more than 70 open enrollment Executive Education programs and 55 custom programs, and HBX, the School’s digital learning platform. For more than a century, HBS faculty have drawn on their research, their experience in working with organizations worldwide, and their passion for teaching to educate leaders who make a difference in the world, shaping the practice of business and entrepreneurship around the globe.

About 2U, Inc. (NASDAQ: TWOU)
2U partners with great colleges and universities to build what we believe is the world’s best digital education. Our platform provides a comprehensive fusion of technology, services and data architecture to transform high-quality and rigorous campus-based universities into the best digital versions of themselves. 2U’s No Back Row® approach allows qualified students and working professionals around the world to experience a first-rate university education and successful outcomes. To learn more, visit 2U.com.

Media Contacts:

Brian Kenny
Chief Marketing and Communications Officer
Harvard Business School
bkenny@hbs.edu
617-495-6336

Jemila Woodson
Senior Communications Manager
2U, Inc.
jwoodson@2u.com
301-892-4419

$MYOK Positive Topline Results, Phase 2 PIONEER-HCM Study in oHCM

• Phase 2 Study Met Primary and Key Secondary Endpoints
• Results from First Patient Cohort of PIONEER-HCM Accepted for Oral Presentation at Heart Failure Society of America’s 21st Annual Scientific Meeting
• Enrollment Complete in Second, Low-Dose Patient Cohort; Topline Data Expected Q1 2018
• Company to Discuss Results on Conference Call Today at 8:30 a.m. EDT (5:30 a.m. PDT)

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 —  MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced positive topline data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients. This cohort met the primary endpoint of change in post-exercise peak left ventricular outflow tract (LVOT) gradient from baseline to week 12 as well as key secondary endpoints, including peak oxygen consumption (peak VO₂). Based on these results and subject to discussions in the coming months with the U.S. Food and Drug Administration (FDA), MyoKardia is planning for its next study, EXPLORER-HCM, to be a pivotal study. EXPLORER-HCM is expected to initiate by the end of this year.

“We are very encouraged by the observed physiological effects of mavacamten in this study,” said Stephen Heitner, M.D., director of the HCM Clinic at Oregon Health and Science University’s Knight Cardiovascular Institute, and the lead investigator in the PIONEER-HCM study. “These results continue to build the body of evidence linking the mechanistic hypothesis of mavacamten to potential clinical benefit in symptomatic, obstructive HCM patients.”

In this first patient cohort of PIONEER-HCM, 11 patients enrolled and 10 completed the study. A statistically significant improvement was observed in the primary endpoint, change in post-exercise peak LVOT gradient from baseline to week 12 (p=0.002).

After 12 weeks of treatment, all 10 subjects (100%) achieved a reduction in post-exercise peak LVOT gradient from a baseline mean of 125 mmHg. In eight of the 10 subjects, the post-exercise peak LVOT gradient was reduced below the diagnostic threshold for oHCM (≤ 30 mmHg), with the other two patients’ measurements below 50 mmHg. Clinically meaningful improvements (≤ 30 mmHg) in resting LVOT gradient were observed as early as week 2 in nine out of 10 subjects, providing the rationale for the addition of a second, low-dose cohort to the PIONEER study. Additionally, clinically and statistically significant improvements were observed in peak VO₂ (p=0.004).

The following table summarizes the results observed in post-exercise peak LVOT gradient and peak VO­₂:

With respect to New York Heart Association Functional Classification, an exploratory endpoint of PIONEER-HCM, improvements from baseline were observed at week 12 (p=0.016), by at least one class in seven patients, with two of these patients improving by two classes.

Mavacamten was generally well-tolerated. One patient with a history of paroxysmal atrial fibrillation experienced a serious adverse event. In order to participate in the study, this patient had discontinued background beta blocker and disopyramide therapy, both of which are indicated for the management of atrial fibrillation. During the study, the patient experienced a recurrent episode of atrial fibrillation and was cardioverted. The patient had another episode of atrial fibrillation and was hospitalized and successfully treated with anti-arrhythmic therapy. The patient elected to stop study drug at week 4. All other adverse events (AEs) were mild to moderate, and a majority of the AEs were deemed to be unrelated to study drug.

After reviewing safety data from PIONEER-HCM, the Independent Data Monitoring Committee (IDMC) recommended continuation of the study.

In the coming months, MyoKardia intends to discuss the mavacamten clinical development plan in an End-of-Phase 2 meeting with the FDA and seek feedback on the potential for EXPLORER-HCM, its next study of mavacamten in symptomatic oHCM, to be a pivotal study with peak VO₂ as the primary endpoint. The key inclusion and exclusion criteria for EXPLORER-HCM are anticipated to be similar to those for PIONEER-HCM, and the Company expects to enroll between 200 and 250 patients in EXPLORER-HCM. The Company expects to initiate EXPLORER-HCM before the end of this year.

“We are delighted by the positive data released today from PIONEER-HCM,” said Marc Semigran, M.D., chief medical officer of MyoKardia. “We believe these results further demonstrate the potential of mavacamten in oHCM and we intend to move decisively and with urgency to develop this potential therapy for patients. We look forward to discussing with FDA the potential for EXPLORER-HCM to serve as a pivotal study.”

“Hypertrophic cardiomyopathy is an area of critical unmet medical need,” said Anthony Muslin, M.D., Head of Cardiovascular Research at Sanofi S.A. (Sanofi), collaboration partner with MyoKardia. “The PIONEER-HCM study of mavacamten and its early results mark a milestone in the development of a potentially transformative therapy for patients with this genetic heart disease.”

MyoKardia also announced today that the second, low-dose patient cohort in PIONEER-HCM has completed enrollment. Given the marked improvement observed in patients in the first cohort within the first two weeks of dosing, the Company added this patient cohort to explore lower daily doses of mavacamten. This second cohort did not require discontinuation of beta blocker therapy prior to enrollment. The Company expects to release topline data from this second patient cohort in the first quarter of 2018.

On behalf of the PIONEER-HCM investigators, Dr. Heitner will present results from the first cohort at the Heart Failure Society of America’s 21st Annual Scientific Meeting on Monday, September 18, 2017 in the “Big Trials of the Last Year” session.

Conference Call and Webcast

MyoKardia will host a conference call and live audio webcast on Monday, August 7, 2017 at 8:30 a.m. EDT / 5:30 a.m. PDT. The call may be accessed by phone by calling (844) 494-0193 from the U.S. and Canada or (508) 637-5584 internationally and using the conference ID 62326435. The webcast may be accessed live on the Investor Relations section of the Company’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the call.

PIONEER-HCM Study Design

PIONEER-HCM is a Phase 2 open-label study to assess the efficacy, safety, pharmacokinetics, pharmacodynamics, and tolerability of mavacamten in patients with symptomatic oHCM. oHCM patients with left ventricular ejection fraction (LVEF) ≥ 55%, LVOT gradient (resting gradient ≥ 30 mmHg, post-exercise peak LVOT gradient ≥ 50 mmHg) and New York Heart Association (NYHA) Class ≥ II were treated with mavacamten for 12 weeks, followed by a four-week washout phase. The primary endpoint of PIONEER-HCM is the change in post-exercise peak LVOT gradient from baseline to week 12. Additional endpoints include change from baseline to week 12 in peak VO₂, VE/VCO₂, NYHA Class, NT-proBNP, rest and exercise LVEF, and dyspnea score. Safety endpoints include treatment-related AEs and serious AEs, and changes from baseline in laboratory test results, vital signs, and electrocardiograms. PIONEER-HCM consists of two dosing cohorts: the first cohort, in which subjects received a 10 mg or 15 mg daily dose and were required to discontinue background therapy including beta blockers, and the second cohort, in which subjects will receive a lower daily dose and are not required to discontinue beta blocker therapy.

About Mavacamten (Formerly MYK-461)

Mavacamten is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in a Phase 1 clinical study of HCM patients. MyoKardia has evaluated mavacamten in multiple Phase 1 clinical studies, primarily designed to evaluate safety and tolerability of oral doses of mavacamten, and provide pharmacokinetic and pharmacodynamic data. In April 2016, the U.S. FDA granted Orphan Drug Designation for mavacamten for the treatment of symptomatic oHCM, a subset of HCM. MyoKardia is currently studying mavacamten in the Phase 2 PIONEER-HCM study.

About MyoKardia

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461). Mavacamten is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in Phase 1 clinical studies of HCM patients. In April 2016, the FDA granted Orphan Drug Designation for mavacamten for the treatment of symptomatic oHCM, a subset of HCM. MyoKardia is currently studying mavacamten in PIONEER-HCM. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia and Sanofi entered into a worldwide collaboration in 2014 for the research, development and potential commercialization of therapies to treat hypertrophic and dilated cardiomyopathy, as well as potential additional indications. The collaboration was a result of Sanofi’s Sunrise Initiative. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten (formerly MYK-461) and MYK-491, the Company’s expectations with respect to the timing of the release of topline data from the second patient cohort of PIONEER-HCM, the Company’s ability to continue to advance mavacamten in the PIONEER-HCM study and MYK-491 in its Phase 1 study in healthy volunteers and its expectations with respect to the timing of the release of data from this study, the Company’s ability to initiate its planned double-blind, placebo-controlled study of mavacamten (EXPLORER-HCM) in symptomatic oHCM and its expectations that it will be considered a pivotal study, the anticipated inclusion and exclusion criteria and number of patients expected to be enrolled in EXPLORER-HCM, the Company’s plans to expand the clinical investigation of mavacamten to patients with non-obstructive HCM in a planned Phase 2 study, and the timing of the initiation of these studies, the Company’s expectations with regard to its End-of-Phase 2 meeting with the FDA, as well as the requirements for registration of the Company’s product candidates, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which we expect to be filed on or about August 7, 2017, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com

Media Contact:
Steven Cooper
Edelman
415-486-3264
steven.cooper@edelman.com

$NETE PayOnline Launches Support for Electronic Commerce in the United States

Fully integrated global payment acceptance is now available through the centralized global platform

$CIIX Appoints Keevin Gillespie President OF ChineseHempOil.com, Inc. Subsidiary

SAN GABRIEL, California, August 7, 2017 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces that it has appointed Keevin Gillespie acting President of its wholly-owned subsidiary, ChineseHempOil.com, Inc., effective immediately. Mr. Gillespie will report directly to CIIX CEO, Warren Wang, and will be responsible for overseeing new business development, marketing and company operations throughout the North American market. Mr. Gillespie’s initial focus will be on promotion and branding of the Company’s newly launched health product line, ‘OptHemp’, which will be marketed through multiple sales channels, including online sales, retail sales, and third party distribution relationships with other health product retailers including acupuncturists, spas, chiropractic centers, etc. Mr. Gillespie is also spearheading the development of the Company’s network marketing division which is in early stage development.

“I’m honored to serve as the President of ChineseHempOil.com, Inc.,” says Mr. Gillespie. “As the many potential health benefits of hemp continue to be revealed through scientific research and development, I believe the Chinese community will embrace this rediscovered ancient remedy. I look forward to creating brand awareness and exposure for the Company’s ‘OptHemp’ product line, developing the Company’s network marketing division and generating significant new revenue streams for the Company in the coming year.”

Through Mr. Wang’s continued leadership as CEO of CIIX, Mr. Gillespie’s leadership as the President of ChineseHempOil.com, Inc., and Summer Yun’s leadership as the recently appointed CEO of CBD Biotechnology Co., Ltd, the Company hopes to ensure that its core financial services/media division and its newly developed direct-to-consumer division achieve their individual growth objectives set out for the coming year. Chinesefn.com will continue to focus on the development of its live video platform focusing on analysis of US stock markets, while ChineseHempOil.com and CBD Biotechnology Co. Ltd. will focus on direct-to-consumer sales of non-industrial hemp health and cosmetic products and other health-related products in the US and China.

“We are excited to name Keevin Gillespie as the President of ChineseHempOil.com, Inc.,” says Wang. “I have known Mr. Gillespie for over 20 years. Early on, he worked as Vice President of sales for the Company and was integral in helping me to build CIIX into what it is today. I’ve known Mr. Gillespie to demonstrate remarkable influence and motivation in his management style, which is why I hand picked him for this leadership position with ChineseHempOil.com, Inc. Mr. Gillespie is also a strong recruiter with extensive sales management experience, and an aptitude for business development. Most importantly, Mr. Gillespie is passionate about our ‘OptHemp’ product line and about the development of a network marketing division. I am confident in his ability to oversee the operations of ChineseHempOil.com. With the appointment of Mr. Yun and Mr. Gillespie, I can dedicate my attention to the Company’s core financial services/media business. Our US stocks live video platform will continue to deliver real-time market commentary, investing highlights, stock analysis and trading callouts to our paid subscribers. In addition, we will continue to develop and improve the live video platform to attract more analysts and to include more trading varieties, including options, futures and forex.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational-related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation-related support services; and (c) retail, online and direct sales of hemp-based products and other health-related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

$QIWI & Tochka Bank Agree on a Partnership in the Small Business Sector

NICOSIA, Cyprus, Aug. 04, 2017 — QIWI plc, (NASDAQ:QIWI) (MOEX:QIWI) (“QIWI” or the “Company”) announced that Tochka Bank (a small-business-focused arm of Otkritie Bank) and QIWI have agreed to partner in the small business sector. QIWI Bank will service small businesses based on a platform developed by Tochka. In order to achieve this, Tochka will grant QIWI Bank the rights to use its technologies, and provide methodological support for launching the platform and achieving consistently high standards of customer service. In turn, Tochka’s clients will be able to use QIWI’s network to receive payments from their customers.

Evgeny Dankevich, Chairman of Otkritie Bank’s Management Board: “Tochka is a successful independent project, one of Otkritie’s best projects. Tochka’s online banking service has won as many as three awards from the Business Internet Banking Rank 2017 by Markswebb: The Best Bank for Sole Traders, The Best Bank for Merchant Companies and The Best Bank for Businesses Involved in Foreign Trade. The new type of partnership we are launching together with QIWI will provide the clients with the opportunity to use the best services available in the market today. Apart from the increased customer satisfaction, this project has additional monetization potential for both Otkritie and QIWI, including through cross sales and cost reduction: instead of investing in the development of similar services of their own, both companies will be able to use each other’s turnkey solutions.”

Boris Dyakonov, Managing Director of Tochka Bank: “The joint project with QIWI is our first experience in expanding our business in collaboration with a partner; in due course, we may look into the possibility of teaming up with other companies, too. I personally think that QIWI is an ideal partner for such a project. The philosophy underlying our services is that we are not just a bank but rather a partner supporting our clients. QIWI shares this philosophy, too, as is evident from the products and services it offers. For example, their cash solutions suit all types of clients – from small stores to supermarkets, from online shops to delivery services.”

Sergey Solonin, CEO of QIWI: “The technological partnership with Tochka is one of the steps in our strategy to develop into a “bank-as-a-service” platform. We are joining forces with like-minded Tochka team to work on creating a new quality of technological environment for the SME segment.”

About QIWI

QIWI is a leading provider of next generation payment services in Russia and the CIS. It has an integrated proprietary network that enables payment services across physical, online and mobile channels. It has deployed over 18.0 million virtual wallets, over 157,000 kiosks and terminals, and enabled merchants to accept over RUB 69 billion cash and electronic payments monthly from over 53 million consumers using its network at least once a month. QIWI’s consumers can use cash, stored value and other electronic payment methods to order and pay for goods and services across physical or online environments interchangeably.

Contact

Varvara Kiseleva
Investor Relations
+357.25028091
ir@qiwi.com

$ARAY First Radixact™ System Research Results at Upcoming AAPM

SUNNYVALE, Calif., Aug. 4, 2017  — Accuray Incorporated (NASDAQ: ARAY) announced today that the first studies validating the benefits of the leading-edge Radixact™ System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Denver, Colorado, July 30 through August 3, 2017. This smart radiation therapy system represents the next generation in TomoTherapy® treatment delivery, significantly increasing treatment speed and ease of use. The Radixact System enables clinicians to treat a wide range of cancer cases, from initial plan delivery to adaptive therapy to complex retreatments, with precision and increased efficiency.

Research highlights include:

Faster planning and reduced treatment time

• A study evaluated the performance of the Radixact System based on a comparison of treatment plans developed for this system and the TomoHDA™ System. Treatment plans were created using the VoLO™ Planning Solution for the TomoHDA technology, then recreated using the Accuray Precision™ Treatment Planning System (TPS) for the Radixact System. Developing optimal plans using the Accuray Precision TPS was much faster, and the treatment beam-on time was reduced by up to 50% while maintaining the excellent plan quality. Researchers at the Miami Cancer Institute in Miami, Florida and Accuray Incorporated conducted the research.

Proven image quality and stability

• The first clinical assessment of Radixact low-dose fan beam MVCT image guidance found there was no statistically significant difference in the noise, uniformity, and Hounsfield units (HU) stability over the three-month evaluation period, demonstrating the strength of the System’s MVCT image quality and its potential value for dose calculation. Clinicians at the Miami Cancer Institute team conducted the research.

Easy installation

• Radixact and TomoTherapy System dosimetric beam characteristics were compared over a six-month period. Radixact data were within the specifications established for the TomoTherapy System and showed a good agreement with the beam model. These results indicate that the beam commissioning process will be straightforward for the Radixact System. Researchers at Miami Cancer Institute and Accuray conducted the study.

The future of radiation therapy

• Two studies demonstrated the feasibility of real-time motion management leveraging the TomoTherapy System’s one-of-a-kind helical delivery capabilities.
  • Accuray researchers investigated the potential for adapting the CyberKnife® System’s unique Synchrony® Respiratory Tracking System to an experimental TomoTherapy System. The study showed Synchrony-like real-time respiratory motion management is technically feasible using TomoTherapy technology, enabling a high level of accuracy when delivering dose to tumors that move with respiration.
  • The dosimetric impact of using real-time primary jaw/multileaf collimator (MLC) compensation approaches to mitigate motion during TomoHelical™ delivery was analyzed by a team of researchers from the University of Wisconsin, Madison and Accuray. Dose was calculated for treatment plans assuming 1) no motion, 2) respiratory motion, and 3) respiratory motion compensated by adjusting the jaw and MLC position during delivery. The team found that a jaw and MLC compensation approach mitigated the large difference between planned and delivered dose caused by motion, thus enabling reductions in margin.

“The data presented at this year’s AAPM speak to the precision, accuracy and effectiveness of Accuray’s entire portfolio of radiation therapy systems,” said Calvin Maurer, Ph.D., Vice President and Chief Technology Officer at Accuray. “The Radixact™ System findings reinforce what customers are experiencing in their day-to-day practice and demonstrate its value to the radiation oncology team and their patients. In partnership with our customers we are continuing to develop clinically relevant technological advances such as the Radixact System, PreciseART™ Adaptive Solution and PreciseRTX™ Retreatment Option, which make it easier for clinicians to provide patients with the best possible treatment for them at each stage of their cancer treatment journey.”

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives.  The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, future developments of our technologies and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 28, 2015, the company’s reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016 and April 29, 2016, and the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events.  The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not put undue reliance on any forward-looking statements.

Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

Danielle Sullivan
MSLGROUP
+1 (781) 684-6680
Danielle.sullivan@mslgroup.com

$MYND Adds Experienced Sales & Marketing Executive

MISSION VIEJO, Calif., Aug. 04, 2017 — MYnd Analytics, Inc. (NASDAQ:MYND), a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error treatment in mental health, announced the addition of Leila Colgan, as Vice President of Sales and Marketing, an experienced diagnostic/pharma executive to its ranks.

Ms. Colgan is an accomplished, results-oriented professional with over 20 years of leadership experience in sales and marketing within the pharmaceutical, biotech and oncology/genomic diagnostic space including organizations such as Clarient, a GE Healthcare Co, (acquired by NeoGenomics in 2015) Amgen, Inc., AstraZeneca, Pfizer (Agouron), Merck & Co. Inc. and Abbott Laboratories. Her depth of industry knowledge and her proven ability to build high-performance teams will be a key in leading the Company’s revenue growth.

Ms. Colgan has consistently exceeded corporate and market share growth targets, and is a recipient of multiple national and local achievement awards throughout her career. She is a visionary executive known for championing business growth and innovation through sales leadership, marketing, business development, and operational oversight while elevating organizations into top revenue-generating entities. An insightful leader with a reputation for forging profitable partner/customer relationships, and aligning sales/promotion functions to maximize revenue and return on investment (ROI), Ms. Colgan received her Bachelor’s of Arts and her Executive MBA from Pepperdine University, graduating with Beta Gamma Sigma Honors.

George Carpenter, MYnd’s CEO, said “Leila’s market expertise, industry connections, sales acumen, and ability to build key relationships will be key to our success, and is a fantastic addition to our growing world class executive team.”

Ms. Colgan stated “I am thrilled to have the opportunity to lead the sales and marketing efforts at MYnd Analytics as we provide better tools for mental health professionals to help decrease trial and error prescribing for their patients.”

About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG).  Based on the Company’s original physician developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.

Forward-looking Statements
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as MYnd’s ability to successfully expand into various market channels, the ability of its products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses and MYnd’s ability to expand globally in areas where there is an opportunity to improve treatment in mental health, as well as those risks and uncertainties set forth in MYnd’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact:
Stan Wunderlich
Investor Relations,CFSG1
800-625-2236
info@cfsg1.com
www.launchpadir.net

$PXS Release Date Set for Financials

Pyxis Tankers Announces Date for the Release of Three and Six Months Ended June 30, 2017 Results

and Related Conference Call and Webcast

MAROUSSI, GREECE – August 4, 2017 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an emerging growth pure play product tanker company, today announced the following:

Date of Earnings Release. We will issue our unaudited results for the three and six months ended June 30, 2017 after the market closes in New York on Thursday, August 10, 2017. We will host a conference call to discuss the results at 4:30 p.m. Eastern Time that same day.

Conference Call Details:

Participants should dial into the call 10 minutes prior to the scheduled time using the following dial-in numbers:

 Webcast:

A live webcast of the conference call will be available through our website (http://www.pyxistankers.com). Webcast participants of the live conference call should register on the website approximately 10 minutes prior to the start of the webcast. An archived version of the webcast will be available on the website within approximately two hours of the completion of the call.

About Pyxis Tankers Inc.

We own a modern fleet of six tankers engaged in seaborne transportation of refined petroleum products and other bulk liquids. We are focused on growing our fleet of medium range product tankers, which provide operational flexibility and enhanced earnings potential due to their “eco” features and modifications. We are well positioned to opportunistically expand and maximize our fleet due to competitive cost structure, strong customer relationships and an experienced management team, whose interests are aligned with those of our shareholders.

 Company
Pyxis Tankers Inc.
59 K. Karamanli Street
Maroussi 15125 Greece
info@pyxistankers.com

Visit our website at www.pyxistankers.com

Company Contact
Henry Williams
Chief Financial Officer
Tel: +30 (210) 638 0200 / +1 (516) 455-0106
Email: hwilliams@pyxistankers.com

$OMER Orphan Drug Designation for OMS721 in IgA Nephropathy

Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. IgA nephropathy is the most common primary glomerulopathy globally, with an estimated 120,000 to 180,000 cases in the U.S. alone, and accounts for up to 10 percent of all dialysis patients. Up to 40 percent of individuals with the disease develop end-stage renal disease, a life-threatening condition, within 20 years following diagnosis.

As previously reported, Phase 2 clinical trial results with OMS721 in IgA nephropathy patients show unprecedented reductions in urine protein levels during and following treatment with OMS721. Elevated urinary protein is highly correlated with poor outcomes in patients with IgA nephropathy. Following review of these data, FDA in June granted OMS721 breakthrough therapy designation for the treatment of IgA nephropathy. Omeros plans to begin enrolling patients in its Phase 3 registration trial in IgA nephropathy later this year.

“Working with FDA, we are initiating another Phase 3 program for OMS721 – this one in IgA nephropathy, which has been granted both breakthrough and orphan designations,” stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “This marks the second Phase 3 program for OMS721, joining our ongoing aHUS program that already has received fast track status from FDA. A third Phase 3 program for OMS721 could be added as well this year in stem cell transplant-associated thrombotic microangiopathy that, together with aHUS, has been granted orphan designation. Focused on bringing OMS721 to market as quickly as possible, we are excited about its prospects and the benefits that we expect OMS721 will provide for patients across a wide range of serious and life-threatening disorders.”

FDA grants orphan designation to promote the development of a drug that is expected to have significant therapeutic advantage over existing treatments that target a condition affecting 200,000 or fewer U.S. patients annually. It qualifies a company for benefits that apply across all stages of drug development, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and waiver of certain administrative fees.

To date, more than 150 subjects worldwide have received OMS721, and no safety concerns have been noted.

About Omeros’ MASP Programs

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. MASP-2 is the effector enzyme of the lectin pathway, one of the principal complement activation pathways. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. MASP-2 is generated by the liver and is then released into circulation. Adult humans who are genetically deficient in one of the proteins that activate MASP-2 do not appear to be detrimentally affected by the deficiency. OMS721 is Omeros’ lead human MASP-2 antibody.

Following discussions with both the FDA and the European Medicines Agency, a Phase 3 clinical program for OMS721 in atypical hemolytic uremic syndrome (aHUS) is in progress. Also, two Phase 2 trials are ongoing. One is evaluating OMS721 in glomerulonephropathies, which has generated positive data in patients with immunoglobulin A (IgA) nephropathy and with lupus nephritis; the other has reported positive data both in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TMA) and in those with aHUS. Based on the positive Phase 2 data, a second Phase 3 clinical program for OMS721 is being initiated in IgA nephropathy and a third Phase 3 program could begin later this year in stem cell transplant-associated TMA. OMS721 can be administered intravenously, and Omeros also expects to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection. In parallel, Omeros is developing small-molecule inhibitors of MASP-2. Based on requests from treating physicians, Omeros has established a compassionate-use program for OMS721, which is active in both the U.S. and Europe. The FDA has granted OMS721 breakthrough therapy designation for IgA nephropathy, orphan drug status for the prevention (inhibition) of complement-mediated TMAs and for the treatment of IgA nephropathy, and fast track designation for the treatment of patients with aHUS.

Omeros also has identified MASP-3 as responsible for the conversion of pro-factor D to factor D and as a critical activator of the human complement system’s alternative pathway. The alternative pathway is linked to a wide range of immune-related disorders. In addition to its lectin pathway inhibitors, the company is advancing its development of antibodies and small-molecule inhibitors against MASP-3 to block activation of the alternative pathway. Omeros is preparing to initiate manufacturing scale-up of its MASP-3 antibodies in advance of clinical trials.

About Omeros Corporation

Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Part of its proprietary PharmacoSurgery^® platform, the company’s first drug product, OMIDRIA^® (phenylephrine and ketorolac injection) 1% / 0.3%, was broadly launched in the U.S. in April 2015. OMIDRIA is the first and only FDA-approved drug (1) for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain and (2) that contains an NSAID for intraocular use. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington’s disease and cognitive impairment; and addictive and compulsive disorders. In addition, Omeros has a proprietary G protein-coupled receptor (GPCR) platform and controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development. The company also exclusively possesses a novel antibody-generating platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

$RWLK Foundational Study Shows Soft Suit Exoskeleton Improves Walking for Stroke Survivors

Study Examines Use of Restore™ System Developed by Harvard’s Wyss Institute

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Aug. 2, 2017 — A new study published in the Journal of Science Translational Medicine finds that use of a soft suit exoskeleton system facilitates normal walking ability for ambulatory patients following a stroke. The paper, which is authored by researchers at Harvard University’s Wyss Institute for Biologically Inspired Engineering and Boston University, is a seminal study, providing key findings that will propel additional research of how to improve mobility for patients following a stroke.

The prototype utilized in the study is a soft suit exoskeleton created by the Wyss Institute that is now moving towards commercialization by ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”).  The study included 9 participants, and examined the immediate improvements in walking capability that could be obtained when wearing the Restore system. The study highlighted the potential for the technology to provide gait assistance and training during walking and concludes:

These improvements in paretic limb function contributed to a 20 +/- 4% reduction in forward propulsion interlimb asymmetry and a 10 +/- 3% reduction in the energy cost of walking, which is equivalent to a 32+/- 9% reduction in the metabolic burden associated with poststroke walking.  Relatively low assistance (~12% of biological torques) delivered with a lightweight and nonrestrictive exosuit was sufficient to facilitate more normal walking in ambulatory individuals after stroke.

 “This foundational study shows that soft wearable robots can have significant positive impact on gait functions in patients post-stroke, and it is the result of a translational-focused multidisciplinary team of engineers, designers, biomechanists, physical therapists and most importantly patients who volunteered for this study and gave valuable feedback that guided our research,” said Wyss Core Faculty member Conor Walsh who is also the John L. Loeb Associate Professor of Engineering and Applied Sciences at SEAS and the Founder of the Harvard Biodesign Lab.

ReWalk is working with the Wyss Institute on the development of lightweight designs to complete clinical studies, pursue regulatory approvals and commercialize the systems on a global scale. The first commercial application will be for stroke survivors, followed by Multiple Sclerosis patients and then additional applications.  There are an estimated 3 million stroke survivors with lower limb disability in the U.S.

“Exoskeletons are now a commercially available, disruptive technology that have changed the lives of many individuals in the paraplegic community,” said ReWalk CEO Larry Jasinski. “The ongoing research at the Wyss Institute on soft exosuits adds a new dimension to exoskeletons that can potentially meet the needs of individuals that have had a stroke, as well as for those diagnosed with Multiple Sclerosis, Parkinson’s disease or people who have limitations in walking. The Restore is a unique lightweight design that can assist and constantly adjust in real time to the user’s needs on every step they take. The depth of this fundamental science is a meaningful element in applying research to the everyday needs of this patient community.”

The Restore transmits power to key joints of the legs with cable technologies, powered with software and mechanics that are similar to the technologies used in the ReWalk exoskeleton system for individuals with spinal cord injury. The cables are connected to fabric-based designs that attach to the legs and foot, thus lending the name “soft suit.”

The full article in the Journal of Science Translational Medicine can be downloaded here.

About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets, expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk’s management for the financial statements for fiscal 2016 and the first quarter of 2017, and the opinion of ReWalk’s auditors in their report on the Company’s financial statements for fiscal 2016, that there are substantial doubts as to ReWalk’s ability to continue as a going concern; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory developments with respect to, ReWalk’s mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk’s initial public offering; ReWalk’s ability to repay its secured indebtedness; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and that the risk that such financings may dilute our shareholders or restrict our business; ReWalk’s ability to use effectively the proceeds of its 2016 follow-on offering; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; the impact of the market price of our ordinary shares on the determination of whether we are a passive foreign investment company;  and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 10-K for the year ended December 31, 2016, as amended, filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

$CERS Enters Into $40 Million Amended Growth Capital Agreement

CONCORD, Calif.

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a $40 million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide. Under the amended facility, Cerus received an immediate $30 million loan at closing on July 31, 2017 and has the option to draw another $10 million subject to achieving a specified revenue milestone.

“Oxford continues to be an invaluable partner. Their appreciation of our business opportunity and shared belief in our mission to establish INTERCEPT as the standard of care for transfused blood components globally strengthens our relationship,” said Kevin D. Green, vice president, finance and chief financial officer of Cerus Corporation. “The non-dilutive capital and potential access to additional proceeds provides us with financial flexibility to help us execute on our commercial growth strategy, as well as to support key clinical programs.”

“A portion of the proceeds from the initial $30 million loan were used to repay the outstanding term loans of approximately $17.6 million provided under the original agreement with Oxford. The amended facility provides Cerus with not only additional capital but also deferred amortization for 18 to 24 months,” continued Green.

“We are pleased to extend our collaboration with Cerus in support of its commercial growth initiatives,” said Christopher A. Herr, senior managing director at Oxford Finance. “Cerus’ commitment to improving patient care, its seasoned management team, and proprietary technology provides us with an attractive lending opportunity.”

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus.

Forward-Looking Statements

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ expectations, opportunities and prospects, including statements concerning the availability of the second term loan of $10 million provided for under the amended credit facility with Oxford, Cerus’ mission to establish INTERCEPT as the standard of care for transfused blood components globally, Cerus’ execution on its commercial growth strategy, and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the satisfaction of the conditions to the funding of the second term loan of $10 million provided for under the amended credit facility with Oxford and Cerus’ ability to maintain (and otherwise comply with the covenants in) the amended credit facility with Oxford; risks associated with Cerus’ ability to meet its debt service obligations and its need for additional funding; risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System; risks associated with Cerus’ lack of commercialization experience in the United States and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System for platelets and plasma in the United States; risks related to Cerus’ ability to commercialize the INTERCEPT Blood System in the United States without infringing on the intellectual property rights of others; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; the uncertain and time-consuming development and regulatory process, including the risks (a) that Cerus may be unable to comply with the FDA’s post-approval requirements for the INTERCEPT platelet and plasma systems, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval for the INTERCEPT platelet and/or plasma systems, (b) related to Cerus’ ability to expand the label claims and product configurations for the INTERCEPT platelet and plasma systems in the United States, which will require additional regulatory approvals and (c) that Cerus may be unable to obtain any regulatory approvals of the INTERCEPT red blood cell system in a timely manner or at all; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or weakening economic conditions in the markets where Cerus sells its products; Cerus’ reliance on third parties to market, sell, distribute and maintain its products; Cerus’ ability to maintain an effective manufacturing supply chain, including the ability of its manufacturers to comply with extensive FDA and foreign regulatory agency requirements; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of future revenues and other financial performance and results, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including Cerus’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 4, 2017. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

$LIVE Open-Market Purchase of 79,000 Shares Under Stock Repurchase Program

LAS VEGAS, Aug. 02, 2017 – Live Ventures Incorporated, (Nasdaq:LIVE), (the “Company”), a diversified holding company, today confirms that it has been actively repurchasing stock on the open market under its stock repurchase program resulting in the accumulation of approximately 79,000 shares since inception of the program through July 2017.  These shares represent approximately four percent of the total common shares of Live Ventures. The shares were purchased at an average price of $10.27 per share.

“Management and long term stockholders are thankful and applaud the opportunity to repurchase shares of our company at what we strongly believe is a significant discount to the company’s intrinsic value,” said Jon Isaac, CEO of Live Ventures.  “We believe these purchases are, by far, the best use of our stockholders’ money at this time.”

In addition to the approximately 79,000 shares repurchased under the stock repurchase program, Mr. Isaac, and Director, Dennis Gao have personally acquired 62,248 shares and 12,650 shares, respectively.  In the meantime, the company will continue to aggressively repurchase shares as opportunity in the market arises.

About Live Ventures Incorporated
Live Ventures Incorporated is a diversified holding company with several wholly owned subsidiaries and a strategic focus on acquiring profitable companies that have demonstrated a strong history of earnings power.  Live Ventures Incorporated provides, among other businesses, marketing solutions that boost customer awareness and merchant visibility on the Internet.  The Company operates a deal engine, which is a service that connects merchants and consumers via an innovative platform that uses geo-location, enabling businesses to communicate real-time and instant offers to nearby consumers.  In addition, it maintains, through its subsidiary, ModernEveryday, an online consumer products retailer and, through its subsidiary, Marquis Industries, a specialty, high-performance yarns manufacturer, hard-surfaces re-seller, which is a top-10 high-end residential carpet manufacturer in the United States.  Marquis Industries, through its A-O Division, utilizes its state-of-the-art yarn extrusion capacity to market monofilament textured yarn products to the artificial turf industry.  Marquis is the only manufacturer in the world that can produce certain types of yarn prized by the industry.  Most recently, the company acquired Vintage Stock, Inc., an award-winning entertainment  company featuring movies, classic and new video games, music, collectible comics and toys, and the ability to special order and ship product worldwide to the customer’s doorstep. Vintage Stock is America’s largest entertainment superstore chain.

Forward-Looking and Cautionary Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, involve risks and uncertainties that may affect the Company’s actual results. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Live Ventures Incorporated may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K, in its annual report to stockholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance.  The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company’s Form 10-K for the fiscal year ended September 30, 2016, most recent Form 10-Q, and other filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:
Live Ventures Incorporated
Tim Matula, investor relations
425-836-9035
tmatula@live-ventures.com
http://www.live-ventures.com

$CIIX Senate Appropriations Committee Adds Fuel to Red-Hot Legal Cannabis Space Fire

August 2, 2017

$IPHS Declares Quarterly Dividend

CRANBURY, N.J., Aug. 1, 2017 — Innophos Holdings, Inc. (Nasdaq: IPHS), today announced that its Board of Directors had declared a quarterly dividend of $0.48 per share of common stock. The dividend will be payable on September 6, 2017 to stockholders of record as of the close of business on August 18, 2017.

About the Company

Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious and economical.  Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico and China. For more information, please visit www.innophos.com. ‘IPHS-G’

$MTBC Q2 2017 Financial Results and Conference Call on August 3

$MOXC Announces Date of Its Annual Meeting of Stockholders

SHENZHEN, China, Aug.1, 2017 — Moxian, Inc. (“Moxian” or the “Company”) (Nasdaq: MOXC), an offline-to-online (O2O) integrated social media platform operator, today announced that it plans to hold its 2017 Annual Meeting of Stockholders at 10:00AM local time on September 29, 2017, which is 10:00PM ET on September 28, 2017, at Regal Hong Kong Hotel, 88 Yee Wo Street, Causeway Bay, Hong Kong. The record date for the Annual Meeting is August 26, 2017.

Rule 14a-8 Stockholder Proposal Deadline

The Company did not hold an annual meeting last year. As a result, under Rule 14a-8 under the Securities Exchange Act of 1934, as amended, the deadline for the receipt of any stockholder proposals submitted pursuant to Rule 14a-8 for inclusion in the Company’s proxy materials for the 2017 Annual Meeting is required to be a reasonable time before the Company begins to print and mail the proxy materials. Taking into consideration the time and process for addressing any deficiencies in proposals that may be submitted, the Company has determined that August 13, 2017 should be the deadline for receipt of proposals pursuant to Rule 14a-8. Such proposals should be delivered to: Block A, 9/F, Union Plaza, 5022 Binjiang Avenue, Futian District Shenzhen City, Guangdong Province, China, Attention: Corporate Secretary. Such proposals will need to comply with the rules of the Securities and Exchange Commission regarding the inclusion of stockholder proposals in the Company’s proxy materials, and may be omitted if not in compliance with applicable requirements.

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.

Forward-Looking Statements

This press release may contain information about Moxian’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Moxian encourages you to review other factors that may affect its future results in Moxian’s registration statement and in its other filings with the Securities and Exchange Commission.

For more information, please contact:

At the Company

Victor Tuang
Phone: + 86 755 83580755
zhuang.gengyong@moxiangroup.com

Investor Relations

Tony Tian, CFA
Weitian Group LLC
Phone: +1-732-910-9692
moxc@weitian-ir.com

$MKGI Definitive Agreements For $3 Million Private Placement; Preps for NASDAQ Listing

$IGC Adds Industry Leader Dr. Chuanhai Cao, expert on THC-Based Alzheimer’s Treatments

BETHESDA, Md., Aug. 01, 2017 — India Globalization Capital, Inc. (NYSE-MKT:IGC) is pleased to announce that Dr. Chuanhai Cao has joined its medical research team as a key Advisor.

Dr. Cao is Associate Professor of Pharmaceutical Sciences, at the University of South Florida’s (USF) College of Pharmacy. He also has joint appointments as Associate Professor at USF’s department of Neurology at the College of Medicine, and the department of CMMB at the College of Arts and Sciences.

“The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials.  Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for an Investigational New Drug (IND) application with the FDA.  Dr. Cao is the perfect researcher to assist us in moving our THC-based Alzheimer’s treatment into trials and potentially into a blockbuster product.  The addition of Dr. Cao to the core group of medical and science advisors consisting of Dr. Craig Cheifetz, Dr. Ranga Krishna and Dr. James Saunders greatly strengthens our team as we seek to move our four products towards commercialization,” concludes Ram Mukunda, CEO.

Dr. Cao conducted the research underlying USF’s patent filing for the use of THC as a potential therapeutic agent for Alzheimer’s. The lab experiments using an animal model led to the publication of findings that THC has the potential to inhibit amyloid beta peptide aggregation and possibly restore memory function, halting the progression of Alzheimer’s disease.  IGC recently acquired exclusive rights to this patent filing from USF.

Dr. Cao has a PhD, in Medical Microbiology and Virology, from Tianjin Medical University, China.  He has authored or co-authored around 80 peer-reviewed articles.  He has been quoted in Huffington Post, USA Today, and was featured in the CNN documentary WEED 3 The Marijuana Revolution by Dr. Sanjay Gupta. Dr. Cao’s interview can be viewed at https://vimeo.com/137431143#t=1818s.

“I became particularly interested in Alzheimer’s disease, especially after the diagnoses of a few individuals close to me.  In 2001, led by co-authors, including well-respected Alzheimer’s pathology researchers at USF, I contributed to my (then) first published paper on responses in experimental mice to a vaccination for the Alzheimer’s disease-associated beta amyloid 1-42 peptide.  I would then go on to co-author over 10 papers studying beta amyloid in Alzheimer’s mice, with a focus on potential treatments.  In 2008, I helped to first-author two papers reporting on potential vaccines for Alzheimer’s disease. The first described the studying and adjuvant-free vaccination using mutated amyloid beta peptides, and the second tested mutant amyloid-beta-sensitized dendritic cells as a possible vaccine. I was also head of a patent on amyloid beta peptides and methods of use. In 2012, I first-authored a book chapter on amyloid beta vaccination strategies, and am currently pursuing a patent on immunomodulatory cells as a novel treatment for diseases, in addition to researching the use of cannabinoids for preventing amyloid beta aggregation.” stated Dr. Cao.

About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us.
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/.

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10 K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998